BiVictriX Therapeutics plc (AIM: BVX), an emerging biotechnology company applying a novel approach to develop next generation cancer therapies using insights derived from frontline clinical experience, today announces that Oliver Schon, VP of Product Development & CMC, will present at the Immuno-Oncology Summit Europe 2022 in London, UK. The conference connects a wide community of pharmaceutical and healthcare professionals and will be held at Hilton London Canary Wharf on 23-25 May 2022.

The event is comprised of three conference programs that cover therapeutic categories;T-Cell and related Cellular Therapeutics, Bi-specific Antibodies and Therapies targeting the Tumour Microenvironment, while a fourth program covers strategies for Therapeutic Development, including Predictive Biomarkers, Preclinical Studies and Translational Studies.

The Company’s presentation will be taking place at 16:45pm BST on 24th May as part of the conference’s Bispecific and Multi specific Antibody Therapeutics section and will discuss the development of a bispecific antibody drug conjugate (ADC) for the treatment of acute myeloid leukaemia (AML).